What is the maximum daily dose of colchicine for an adult with normal renal and hepatic function?

Maximum Daily Dose of Colchicine

For adults with normal renal and hepatic function, the maximum daily dose of colchicine depends on the indication: 1.8 mg/day for acute gout flares (1.2 mg followed by 0.6 mg one hour later, not to be repeated for at least 3 days), 1.2 mg/day for gout flare prophylaxis (0.6 mg twice daily), and up to 2.4 mg/day for Familial Mediterranean Fever (FMF). 1

Dosing by Indication

Acute Gout Flares

• Treatment regimen: 1.2 mg loading dose followed by 0.6 mg one hour later (total 1.8 mg on day 1)
• Critical timing: Must be initiated within 12 hours of flare onset for optimal efficacy 22
• Repeat dosing: Cannot be repeated for at least 3 days 1
• This low-dose regimen is as effective as older high-dose protocols but with significantly fewer gastrointestinal adverse effects 3

Gout Flare Prophylaxis

• Standard dose: 0.6 mg twice daily (1.2 mg/day maximum) 1
• Alternative: 0.5-1 mg/day during the first 6 months of urate-lowering therapy 22
• Prophylaxis prevents flares when initiating urate-lowering therapy

Familial Mediterranean Fever

• Typical range: 1.2-2.4 mg/day 1
• Maximum: 2.4 mg/day has been used safely in FMF patients, particularly in women who may require higher doses 4
• Recent evidence suggests doses up to 2.5 mg/day can be used without toxicity in FMF patients 4

Critical Drug Interactions Requiring Dose Reduction

When co-administered with strong CYP3A4 or P-glycoprotein inhibitors, maximum doses must be substantially reduced 1:

With Strong Inhibitors (cyclosporine, clarithromycin, ritonavir, ketoconazole)

• Gout prophylaxis: Reduce from 1.2 mg/day to 0.3 mg once daily
• Acute gout: Reduce from 1.8 mg to 0.6 mg single dose (no second dose)
• FMF: Reduce from 1.2-2.4 mg/day to 0.6 mg once daily or 0.3 mg every other day
• Absolute contraindication: Do not use colchicine with these inhibitors in patients with renal or hepatic impairment 11

Fatal colchicine toxicity has been reported with cyclosporine co-administration due to massive drug accumulation 11.

Renal Impairment Adjustments

For patients with normal hepatic function but varying renal function 11:

Mild Impairment (CrCl 50-80 mL/min)

• No dose adjustment required
• Monitor closely for adverse effects

Moderate Impairment (CrCl 30-50 mL/min)

• Prophylaxis: No adjustment needed but monitor closely
• Acute gout: No adjustment but do not repeat course more than once every 2 weeks
• FMF: Monitor closely; dose reduction may be necessary

Severe Impairment (CrCl <30 mL/min)

• Prophylaxis: Start at 0.3 mg/day
• Acute gout: Do not repeat course more than once every 2 weeks
• FMF: Start at 0.3 mg/day; titrate cautiously

Dialysis

• Prophylaxis: 0.3 mg twice weekly
• Acute gout: Single 0.6 mg dose; do not repeat more than once every 2 weeks
• FMF: 0.3 mg starting dose

Safety Considerations

The therapeutic index of colchicine is narrow, with no clear distinction between therapeutic, toxic, and lethal doses 5:

• Lethal doses reported as low as 7-26 mg total
• High fatality rate after acute ingestions exceeding 0.5 mg/kg
• Most common adverse effect: diarrhea (RR 1.76) 6
• Other GI effects include nausea, vomiting, cramping 3

Toxicity Phases

1. 0-24 hours: Gastrointestinal phase (may be absent with IV administration)
2. 24 hours-7 days: Multi-organ dysfunction, bone marrow suppression, cardiovascular collapse
3. Recovery phase: Typically within weeks if patient survives 5

High-Risk Scenarios

• Concurrent use of statins increases myopathy risk 5
• Renal impairment patients on prophylaxis should NOT receive additional colchicine for acute flares 1
• Patients on CYP3A4/P-gp inhibitors with renal or hepatic impairment should not receive colchicine 22

Key clinical pitfall: Never combine prophylactic and acute treatment doses—this substantially increases toxicity risk, especially with concurrent drug interactions or renal impairment.